On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, ...
The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.
Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This ...
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...
Cobenfy gives patients an alternative to drugs with troublesome side effects.
Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel ...